KYMERA THERAPEUTICS INC
KYMERA THERAPEUTICS INC logo
KYMR

KYMERA THERAPEUTICS INC (KYMR)

$28.61.17%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$27.9
Day's Range
$29.24
$13.15
52-Week Range
$66.45
1 month return6.82%
3 month return0.53%
1 year return49.08%
5 year return15.0%

Company Information

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
OrganizationKYMERA THERAPEUTICS INC
Employees169
CEODr. Bruce L. Booth D.Phil., DPHIL, Ph.D.
IndustryHealth Technology

Analyst Recommendation

based on 6 analysts ratings

Buy
66%
Buy
33%
Hold
0%
Sell

Based on 6 Wall street analysts offering stock ratings for KYMERA THERAPEUTICS INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 91.89%

Current

$28.6

Target

$54.88

Recommendation Trend

Based on 6 analyst

Current1M Ago3M Ago
Buy
4
18
16
Hold
2
5
5
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.5B
Book Value
$9.41
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.49
Wall Street Target Price
54.88

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
2.97
Enterprise Value
1.1B
Enterprise Value/Revenue
23.03
Enterprise Value/Ebitda
-7.02

Technicals

Beta
1.49
50 Day MA
25.55
200 Day MA
27.68

Institutional Holdings

T. Rowe Price Associates, Inc.

9.52%

Bvf Inc

7.54%

Wellington Management Company LLP

6.22%

Baker Bros Advisors LP

5.25%

Vanguard Group Inc

5.22%

State Street Corporation

4.89%

Discover more

Frequently Asked Questions

What is KYMERA THERAPEUTICS INC share price today?

Can Indians buy KYMERA THERAPEUTICS INC shares?

How can I buy KYMERA THERAPEUTICS INC shares from India?

Can Fractional shares of KYMERA THERAPEUTICS INC be purchased?

What are the documents required to start investing in KYMERA THERAPEUTICS INC stocks?

What are today’s High and Low prices of KYMERA THERAPEUTICS INC?

What are today’s traded volumes of KYMERA THERAPEUTICS INC?

What is today’s market capitalisation of KYMERA THERAPEUTICS INC?

What is the 52 Week High and Low Range of KYMERA THERAPEUTICS INC?

How much percentage KYMERA THERAPEUTICS INC is down from its 52 Week High?

How much percentage KYMERA THERAPEUTICS INC is up from its 52 Week low?

What are the historical returns of KYMERA THERAPEUTICS INC?

Who is the Chief Executive Officer (CEO) of KYMERA THERAPEUTICS INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*